Antibody-drug conjugates (ADCs) link cancer drug payloads, such as tubulin inhibitors and DNA damaging agents, to monoclonal antibodies that selectively target tumor cells. Pernille Hemmingsen, PhD, ...

AsymBio’s Conjugation Toolbox supports customized process development across both random and site-specific conjugation technologies. For IND-enabling programs, conjugation process development ...

Antibody-drug conjugates (ADCs) have revolutionized the oncology field, offering targeted cancer treatments that improve efficacy without adversely affecting healthy cells. 1 ADCs’ potential extends ...

DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

Antibody-drug conjugates (ADCs) have evolved from an elegant scientific concept into one of oncology’s most dynamic therapeutic classes. By fusing the targeting specificity of monoclonal antibodies ...

Dr. Jacob A. Sands shares how antibody-drug conjugates, such as Datroway, work to selectively target and destroy tumor cells among those with lung cancer. Antibody-drug conjugates like Datroway ...

Antibody Drug Conjugates (ADCs) are a class of small molecule drugs (also known as a payload) and an antibody conjugated together by a chemical linker. ADCs are designed to target specific cells, such ...

Researchers used antibody-tagged lipid nanoparticles (LNPs) to redirect cancer therapies to multiple myeloma cells. LNPs with ...

At first glance, there may appear to be little connection between food research and manufacturing and a highly targeted drug-delivery method based on antibodies. But, as they both rely on amino acids, ...